Meeting
2014 ASCO Annual Meeting
Characterization of an anti-Τrop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
Authors
David M. Goldenberg
Immunomedics, Inc., Morris Plains, NJ
David M. Goldenberg , Edmund A Rossi , Serengulam V. Govindan , Thomas M. Cardillo , William J. McBride , Maria Zalath , Gaby Terracina , Preeti Trisal , Robert M. Sharkey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Other
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3107)
DOI
10.1200/jco.2014.32.15_suppl.3107
Abstract #
3107
Poster Bd #
174
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
First Author: Alexander Starodub
Poster
2024 ASCO Annual Meeting
Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.
First Author: Nicholas Mai
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Unveiling proteomic diversity: A quantitative study of antibody drug conjugate and chemotherapy targets in gastroesophageal cancer.
First Author: Sheeno P. Thyparambil
Poster
2023 ASCO Annual Meeting
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.
First Author: Charu Aggarwal